Philips Capital Markets Day 2026 Summary Company Overview - **Company**: Koninklijke Philips (NYSE:PHG) - **Industry**: Health Technology - **Focus**: Innovation in health technology, particularly in diagnosis, treatment, connected care, and personal health Key Points and Arguments Company Strategy and Vision - Philips aims to drive profitable growth and deliver sustainable value through innovation and improved operational performance [3][4][5] - The company has improved its culture, team, and business fundamentals over the past three years, positioning itself for growth acceleration [4][5][10] - Philips has a clear ambition to improve the lives of 2.5 billion people by 2030, building on the 2 billion lives improved by 2025 [8] Market Position and Leadership - Philips holds leading positions in various segments: - Number one in catheterization lab systems, interventional cardiology, cardiac ultrasound, grooming, and medical device integration [3] - Top three in diagnostic imaging and number two in oral health care and sleep and respiratory care [3] - The company has a global footprint with over 2.5 million systems installed, reaching 80% of top hospitals worldwide [19] Financial Performance and Targets - Philips aims for mid-single-digit compound annual growth rate (CAGR) and mid-teens margins by 2028, with strong cash generation of EUR 4.5 billion to EUR 5 billion over the planned period [19][41] - The company has expanded its margins by nearly 500 basis points to over 12% and targets mid-teens margins in the next three years [45] - Cash flow targets include EUR 1.3 billion to EUR 1.5 billion in 2026 and EUR 4.5 billion to EUR 5 billion cumulatively over the planned period [46] Innovation and Product Development - Philips has shifted to a business-led innovation model, focusing on customer needs and accelerating the speed of innovation [12][34] - The company has launched several groundbreaking products, including the world's first helium-free 3T MRI and advancements in ultrasound technology [25][34] - AI and data integration are central to Philips' innovation strategy, enhancing clinical decision-making and operational efficiency [17][36] Operational Improvements - Philips has simplified its operations, reducing overlapping quality management systems by over 75% and improving customer fill rates by more than 20% [14][15] - The company has implemented a decentralized decision-making model, enhancing agility and responsiveness to market demands [15] - A productivity program aims to deliver an additional EUR 1.5 billion in savings over the next three years, focusing on cost competitiveness and lean operations [59][60] Market Dynamics and Growth Opportunities - The healthcare market is projected to grow at 3%-5% annually, driven by an aging population and increasing chronic disease prevalence [16][17] - There is a widening gap between the demand for healthcare services and supply, presenting significant innovation opportunities for Philips [16] - North America is identified as a key growth engine, with double-digit growth observed in 2025 [32] Challenges and Risks - Philips acknowledges the uncertain macro environment, including potential impacts from tariffs and ongoing litigation related to the Respironics recall [46][42] - The company is committed to navigating these challenges while maintaining focus on its strategic goals [42] Conclusion - Philips is positioned for a strong future with a clear strategy focused on innovation, operational excellence, and market leadership in health technology [43][44] - The company emphasizes its commitment to delivering better care for more people while driving profitable growth and creating sustainable value [42][43]

Financial Data and Key Metrics Changes - Order intake increased by 7% in Q4 2025, reflecting sustained improvement over the past year, with comparable sales growth also at 7% year-on-year [5][6] - Adjusted EBITDA margin improved by 160 basis points to 50.1% in Q4, and for the full year, it reached 12.3%, exceeding the outlook despite tariff impacts [5][6][21] - Net income rose to EUR 397 million in Q4, primarily due to improved operational income and lower tax charges, with adjusted diluted earnings per share increasing by 20% year-on-year [24] Business Line Data and Key Metrics Changes - In Diagnosis and Treatment (D&T), comparable sales grew by 4% in Q4, with Image-Guided Therapy achieving double-digit growth, while Precision Diagnosis remained flat [17] - Connected Care delivered 7% comparable sales growth in Q4, driven by double-digit growth in monitoring solutions [18] - Personal Health saw a 14% growth in Q4, supported by strong demand across various product categories, particularly in grooming and beauty [19] Market Data and Key Metrics Changes - North America continued to be the strongest growth driver, with sustained double-digit order intake growth [7][14] - In China, tender activity increased, but the market remains cautious due to longer processing times and tougher competition [14][15] - Europe showed stable capital spending, while select international regions increased healthcare investments, particularly in Indonesia and India [15] Company Strategy and Development Direction - The company is transitioning to a focus on profitable growth acceleration, targeting mid-single-digit sales CAGR and mid-teens margins by 2028 [6][11] - A multi-year roadmap centered on AI-enabled, patient-centric innovations is being executed, with significant product launches planned [10][19] - The company aims to enhance patient impact and quality while simplifying operations and strengthening supply chain resilience [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 with strong order intake momentum and a robust innovation pipeline, despite ongoing tariff challenges [26][81] - The outlook for 2026 includes expected comparable sales growth of 3%-4.5%, with a focus on North America and international regions [16][26] - Management remains cautious about the near-term outlook for China while recognizing its long-term growth potential [14][66] Other Important Information - The company completed the sale of its emergency care business in Q4 as part of its portfolio simplification strategy [19] - A new EUR 1.5 billion productivity program is being launched for the 2026-2028 period to drive further operational improvements [29] Q&A Session Summary Question: Insights on gross margin improvement and order intake for D&T - Management noted that gross margin improvement is driven by innovation and productivity, with continued margin expansion expected despite tariff impacts [34][35] - Order intake for D&T was 5%, with strong contributions from Image-Guided Therapy and ultrasound innovations [37][38] Question: Buffers in the 2026 guidance and margin expectations - Management acknowledged the need for diligence in execution and emphasized that growth will be a significant contributor to margin improvement [41][42] Question: Performance of Precision Diagnosis and Q1 growth phasing - Precision Diagnosis saw stable sales, with expectations for improved momentum in 2026 due to new innovations [49][50] - Q1 is expected to start at the lower end of the growth range due to seasonality and tariff impacts [50][51] Question: Drivers of personal health performance and Section 232 investigation - Strong personal health performance was attributed to market share gains and healthy sell-out trends, with inventory levels now aligned with market averages [56][57] - The Section 232 investigation is ongoing, with potential implications for tariffs, but no definitive outcomes have been shared [58][59] Question: Outlook for China and margin dynamics in personal health - Management remains cautious about the health system side in China while expecting some improvement in personal health sales [66] - The strong margin in personal health is driven by innovation, commercial execution, and productivity improvements [67][68]

Financial Data and Key Metrics Changes - Order intake increased by 7% in Q4 2025, reflecting sustained improvement over the past year [5] - Comparable sales growth was 7% year-on-year, broad-based across all businesses and geographies [5] - Adjusted EBITDA margin improved by 160 basis points to 50.1% in Q4 2025, despite tariff impacts [5] - For the full year, adjusted EBITDA margin was 12.3%, exceeding the outlook [6][24] Business Line Data and Key Metrics Changes - Diagnosis and Treatment (D&T) saw comparable sales growth of 4% in Q4, with strong performance in Image-Guided Therapy [20] - Connected Care delivered 7% comparable sales growth in Q4, driven by double-digit growth in monitoring solutions [21] - Personal Health achieved 14% comparable sales growth in Q4, with all three businesses contributing [22] Market Data and Key Metrics Changes - North America remained the strongest growth driver, with sustained double-digit order intake growth [7][15] - In China, tender activity increased but faced challenges due to centralized procurement, leading to cautious near-term outlook [16][19] - Europe showed stable capital spending, while select international regions increased healthcare investments [17] Company Strategy and Development Direction - The company is focused on profitable growth acceleration, targeting mid-single-digit sales CAGR and mid-teens margins by 2028 [6][12] - Continued emphasis on innovation, particularly AI-enabled and patient-centric solutions, to drive future growth [10][12] - The company is enhancing patient impact and quality while simplifying operations and strengthening supply chain resilience [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 with strong order intake momentum and improved execution [29] - The company expects comparable sales growth of 3%-4.5% in 2026, led by North America and international regions [19][30] - Management remains cautious about the near-term outlook for China but sees long-term growth potential [16][19] Other Important Information - The company generated EUR 1.2 billion in free cash flow in Q4 2025, despite a tougher comparison base [27] - Adjusting items decreased to EUR 179 million in Q4, reflecting a strong commitment to reducing these over time [26] - The company ended the quarter with approximately EUR 2.8 billion in cash and a leverage ratio improved to 1.7 times [28][29] Q&A Session Summary Question: Insights on gross margin improvement and order intake for D&T - Management confirmed gross margin improvement across Philips, driven by innovation and productivity, with continued margin expansion expected in 2026 despite tariff impacts [36][38] - Order intake for D&T was 5%, with strong contributions from Image-Guided Therapy and ultrasound innovations [39][40] Question: Clarification on 2026 guidance and margin buffers - Management acknowledged the dynamic environment and emphasized the importance of productivity and innovation for margin growth [43][44] Question: Performance of Precision Diagnosis and Q1 phasing - Management indicated that Precision Diagnosis returned to growth, with expectations for stronger performance in 2026 driven by new innovations [50][51] - Q1 is expected to start at the lower end of the growth range due to seasonality and tariff impacts [52][53] Question: Drivers behind strong personal health performance - Management highlighted market share gains and strong demand across geographies, with inventory levels now aligned with market averages [58][60] Question: Update on Section 232 investigation - Management stated that the investigation is ongoing, with potential measures that could replace tariffs but refrained from speculation on outcomes [61][62] Question: Outlook for China and margin dynamics - Management expects stable growth in China, with cautious optimism for personal health but uncertainty in health systems due to tender processes [67] - The strong margin in personal health was attributed to innovation, commercial execution, and productivity improvements [70][71]